The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder

Introduction: Major depressive disorder (MDD) is the leading cause of disability worldwide, and according to the STAR*D trial, only 33% of patients with MDD responded to initial drug therapy. Augmentation of the leading class of antidepressant treatment, selective serotonin reuptake inhibitors (SSRI...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Expert Opin Drug Discov
Hauptverfasser: Sahli, Zeyad T., Banerjee, Pradeep, Tarazi, Frank I.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Taylor & Francis 2016
Schlagworte:
Drug Discovery Case History
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4841022/
https://ncbi.nlm.nih.gov/pubmed/26971593
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/17460441.2016.1160051
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge